Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Radiat Oncol. 2022 May 12;17(1):90. doi: 10.1186/s13014-022-02061-y.
Prostate cancer is the second most common malignancy worldwide, and the majority of patients are diagnosed with localized disease. We examined patients' quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
We included patients who were treated between 2016 and 2020. Inclusion criteria were adenocarcinoma of the prostate; class risk of low, intermediate, and high; and a World Health Organization performance status of 0-2. Quality of life was measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P).
A total of 439 patients were treated with SBRT, with a median age of 73 years old. The median follow-up period was 34 months. FACT-P Trial Outcome Index (p < 0.0001), FACT-General (p = 0.0003), and FACT-P-Total (p < 0.0001) scores declined at 1 month post-SBRT, then recovered and returned to the same level as before treatment at 3-4 months post-SBRT. The decrease in quality of life in the first month was particularly remarkable in patients who received long-term hormone injections (36%). One month after the end of SBRT, about 22% of patients experienced "quite a bit" or more troubling side effects.
This study showed longitudinal changes in quality of life by FACT-P after SBRT for prostate cancer. Overall, prostate SBRT was well tolerated.
前列腺癌是全球第二大常见恶性肿瘤，大多数患者被诊断为局限性疾病。我们研究了接受立体定向体部放射治疗（SBRT）的前列腺癌患者的生活质量。
我们纳入了 2016 年至 2020 年间接受治疗的患者。纳入标准为前列腺腺癌；低、中、高危风险分类；以及世界卫生组织体力状况 0-2 级。使用癌症治疗功能评估-前列腺量表（FACT-P）来衡量生活质量。
共 439 例患者接受 SBRT 治疗，中位年龄为 73 岁。中位随访时间为 34 个月。SBRT 治疗后 1 个月 FACT-P 试验结局指数（p<0.0001）、FACT-一般量表（p=0.0003）和 FACT-P 总分（p<0.0001）评分下降，然后在 3-4 个月时恢复并恢复到治疗前的水平。在接受长期激素注射的患者中（36%），生活质量在第一个月的下降尤为显著。SBRT 结束后 1 个月，约 22%的患者出现“相当多”或更多困扰的副作用。
本研究通过 FACT-P 显示了前列腺癌 SBRT 后的生活质量的纵向变化。总体而言，前列腺 SBRT 耐受性良好。
